The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis
Although crizotinib has a well-established role in ROS1+ non-small cell lung cancer (NSCLC), there is a lack in data on the activity of crizotinib in controlling brain disease in ROS1+ patients. The Phase II METROS (NCT02499614) trial was designed to investigate the efficacy of crizotinib in pretreated patients with NSCLC and MET alterations or ROS1 rearrangements. Federico Cappuzzo, MD, PhD, AUSL della Romagna-Ravenna, Ravenna, Italy, shares the results of a long-term analysis of METROS which assessed survival outcomes of ROS1-postitive patients, according to the presence of brain metastasis. A significant benefit was observed in this subgroup of patients in terms of long-term survival. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
